scorecardresearch
Follow Us:
Wednesday, May 12, 2021

New research: Antiviral drug MK-4482 shows promise against Covid-19

MK-4482, delivered orally, is now in human clinical trials. Remdesivir is provided intravenously, making its use primarily limited to clinical settings.

By: Express News Service | New Delhi |
Updated: April 17, 2021 10:54:38 am
antiviral drug, MK-4482, Coronavirus vaccine, Covid vaccination, India Covid vaccines, India foreign vaccines, SARS-CoV-2 infection, Indian ExpressQueue for vaccination against Covid-19 in Mulund, Mumbai. (Express Photo: Deepak Joshi)

An experimental antiviral drug, MK-4482, significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection, according to a new study from scientists from the US National Institutes of Health (NIH), and published in the journal Nature Communications.

MK-4482, delivered orally, is now in human clinical trials. Remdesivir is provided intravenously, making its use primarily limited to clinical settings.

The scientists found MK-4482 treatment effective when provided up to 12 hours before or 12 hours after infecting the hamsters with SARS-CoV-2.

These data suggest that MK-4482 treatment potentially could mitigate high-risk exposures to SARS-CoV-2, and might be used to treat established SARS-CoV-2 infection alone or possibly in combination with other agents.

Source: NIH (US)

📣 The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Explained News, download Indian Express App.

  • The Indian Express website has been rated GREEN for its credibility and trustworthiness by Newsguard, a global service that rates news sources for their journalistic standards.
0 Comment(s) *
* The moderation of comments is automated and not cleared manually by indianexpress.com.
Advertisement
Advertisement
Advertisement
Advertisement
X
x